Table 3. Summary of most frequent adverse events with WHO grade 3 or 4 for patients with relapsed or refractory peripheral T-cell lymphoma treated by various salvage therapy.
| Study (year) | Regimen | No. of Patients treated | Hematological AE (%) | Non-hematological AE (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| leukopenia | neutropenia: | thrombocytopenia: | lymphopenia: | anemia: | hyperkalemia: | |||||
| Enblad et al. (2004) | Alemtuzumab | 14 | 28.5 | 21.4 | 14.2 | NR | ||||
| Foss et al. (2015) | Belinostat | 24 | 62.5 | NR | ||||||
| Damaj et al. (2013) | Bendamustine | 60 | 56 | 38 | infection: 20 | |||||
| Pro et al. (2012) | Brentuximab vedotin | 58 | 21 | 14 | peripheral sensory neuropathy: 12 | |||||
| Horwitz et al. (2014) | Brentuximab vedotin | 35 | 14 | 9 | peripheral sensory neuropathy: 9 | |||||
| Zinzani et al. (2000) | Gemcitabine | 44* | No grade 3 and grade 4 hematologic toxicity | NR | ||||||
| Zinzani et al. (2010) | Gemcitabine | 39* | No grade 3 and grade 4 hematologic toxicity | NR | ||||||
| Morschhauser et al. (2013) | Lenalidomide | 54 | 15 | 20 | gastrointestinal disorder: 17, infection: 15 | |||||
| O'Connor et al. (2011) | Pralatrexate | 111* | 15 | 32 | 18 | mucositis: 22 | ||||
| Coiffier et al. (2012) | Romidepsin | 131 | 20 | 24 | 11 | infection: 19 | ||||
| d’Amore et al. (2010) | Zanolimumab | 21 | NR | NR | ||||||
| Huang et al. (2002) | 13-cRA+interferon-α | 17 | 12 | 12 | infection: 23.5, fever: 12, fatigue: 12 | |||||
| Seok et al. (2012) | A-DHAP | 24 | 79.2 | 16.7 | NR | |||||
| Zelenetz et al. (2003) | ICE | 222* | NR | NR | ||||||
*indicates the statistics including data for some subtype other than PTCL
Abbreviations: A-DHAP: alemtuzumab, AEs, adverse events; dexamethasone, cytarabine, cisplatin; ICE: ifosfamide, carboplatin, etoposide; HDAC: histone deacetylase; PTCL: peripheral T-cell Lymphoma; RR: relapsed or refractory.